Department of Pharmacy, Xijing Hospital, The Fourth Military Medical University, Changle West Street 15, Xi'an, Shaanxi 710032, China.
Eur J Pharmacol. 2013 Jan 15;699(1-3):219-26. doi: 10.1016/j.ejphar.2012.11.005. Epub 2012 Nov 29.
Danshensu, as the effective component of Salvia miltiorrhiza (Danshen), has been widely used in clinic for treatment of cardiovascular diseases in China. In the present study, we aimed to confirm the cardioprotective effect of Danshensu from myocardial ischemia/reperfusion (MI/R) injury in vivo, and investigate the potential molecular mechanisms against simulated ischemia/reperfusion (SI/R) induced cardiomyocytes apoptosis in vitro. The rat model of MI/R injury was induced by a transient vessel occlusion for 30 min and reperfusion for 3h, Danshensu significantly reduced myocardium infarct size and the production of creatine kinase-MB (CK-MB), cardiac troponin (cTnI) in serum. In vitro experiment, H9c2 cardiomyocytes were incubated with vehicle or ischemic buffer during hypoxia, and then it was reoxygenated with or without Danshensu. Danshensu markedly improved cell viability and decreased lactate dehydrogenase (LDH) release. We confirmed anti-apoptotic effect of Danshensu both by flow-cytometric analysis and terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay, and this effect was associated with the increase of Bcl-2/Bax ratio and the decrease of active caspase-3 expression. Western blot analysis also showed that Danshensu increased phosphorylation of Akt and extracellular signal-related kinase 1/2 (ERK1/2) in H9c2 cells, and the protective effects of Danshensu were partially inhibited by phosphatidylinositol 3'-kinase (PI3K) specific inhibitor wortmannin or ERK specific inhibitor U0126. Our results suggested that Danshensu could provide significant cardioprotection against MI/R injury, and the potential mechanisms might to suppression of cardiomyocytes apoptosis through activating the PI3K/Akt and ERK1/2 signaling pathways.
丹参素作为丹参的有效成分,在中国已广泛用于治疗心血管疾病的临床。本研究旨在体内确认丹参素对心肌缺血/再灌注(MI/R)损伤的心脏保护作用,并体外研究其对模拟缺血/再灌注(SI/R)诱导的心肌细胞凋亡的潜在分子机制。通过短暂血管闭塞 30 分钟和再灌注 3 小时诱导大鼠 MI/R 损伤模型,丹参素显著减少心肌梗死面积和血清肌酸激酶同工酶-MB(CK-MB)、心肌肌钙蛋白(cTnI)的产生。在体外实验中,将 H9c2 心肌细胞在缺氧时用载体或缺血缓冲液孵育,然后再用或不用丹参素进行再氧合。丹参素显著改善细胞活力并降低乳酸脱氢酶(LDH)释放。我们通过流式细胞术分析和末端脱氧核苷酸转移酶 dUTP 缺口末端标记(TUNEL)测定证实了丹参素的抗凋亡作用,并且这种作用与 Bcl-2/Bax 比值的增加和活性 caspase-3 表达的降低有关。Western blot 分析还表明,丹参素增加了 H9c2 细胞中 Akt 和细胞外信号调节激酶 1/2(ERK1/2)的磷酸化,并且丹参素的保护作用被磷脂酰肌醇 3'-激酶(PI3K)特异性抑制剂wortmannin 或 ERK 特异性抑制剂 U0126 部分抑制。我们的研究结果表明,丹参素可以对 MI/R 损伤提供显著的心脏保护作用,其潜在机制可能是通过激活 PI3K/Akt 和 ERK1/2 信号通路抑制心肌细胞凋亡。